Really looking forward to attending this years NLS Days in Malmö!

Having attended the past 3 years of the NLS days in Stockholm, this year the event is being held in the heart of Medicon Valley and will be atteneded by a number of other countries as well.

I will be representing Pharma Publications in my role as editor of the International Pharmacetical Industry magazine, I have already started to request partnering meetings which I feel is really a important part of the event so its never to early to start.

I look forward to seeing everyone there!

Great to be presenting at Anglo Nordic on the Nordic Overview for Life Sciences in London!


Lucy Robertshaw will be the chair for the afternoon session of the Biotech Investment Programme at the Anglo Nordic Life Science Confernece in London on Wednesday 31st May.

Biotech Investment Programme

She will also be presenting the Nordic Overview for Life Sciences where it will be presented the events which should not be missed in 2017 being held in Sweden.

LucyJRobertshaw have been the proud co-organisers of the event and have been in attendance for the past 3 years.

Future of Swedish and Danish Life Science event brought together a range of minds

I once again for the 3rd year moderated the Future of Swedish and Danish Life Science at Medicon Village which is in the heart of Medicon Valley and we had a a great time.


New connections were made yesterday when a wide range of people were brought together at the sixth annual international networking forum, The Future of Swedish and Danish life science. Medicon Village joined forces with Kemivärlden Biotech/Journal of Chemistry and Biotechnology and Medicon Valley Alliance to organize the forum.

And they targeted decision makers in the pharma, biotech, medtech and health care sectors, persons from research and development in both industry and academia, along with investors, authorities and politicians. A wide range of participants pointed out the great value in meeting face to face.

– I´m here to be inspired by how I can bridge my public health degree with the pharma industry. This event is bringing many actors together in one spot, where we are able to meet face to face, says Keeva Duffey, mph-student at Lund University.

Some 35 exhibitors and nearly 520 participants engaged in conversations. And they had ample opportunities to make new connections or to touch base on a more informal basis during the frequent coffee breaks.

– We think it´s very interesting and fun to take part and see what´s happening in the world of life science, in particular in this region. Our niche lies within the life sciences, and here we have a big opportunity to meet both clients and potential candidates, Eva Runnerström, recruitment consultant at PeakSearch, points out.

Also a delegate of ten collaboration partners from the U.K keeps Sweden and Denmark on the radar.

– The purpose of coming here is about connections. It´s connections not only in terms of raising our profile here and seeking new clients, but it´s actually new expertise, says Greer Deal, director at GRS® and continues. Who have you got locally, who we can work with, who we can collaborate with? We can bring all that expertise together to provide a holistic solution to our clients in the global life science sector.

Copied from

Stockholm Corporate Finance Life Science Seminar 2017

I attended this years Stockholm Corporate Finance Life Science Seminar which is run every year and this is my 3rd year of attending.

Translated from Swedish Financial newsletter. 

More than 400 people participated in the Stockholm Corporate Finance Ninth Life Science seminar held on 21 and 22 March in cooperation with us at Financial Hearings and the news agency Direct. There were 16 companies that presented. These corresponding to a total market value of approximately SEK 15 billion. Investor Interest in Life Science sector continues to increase among both institutions, asset managers and private equity investors.

SCFs CEO Peter Enstrom began by informing about the present, 16 companies are an important part of the Swedish Life Science industry. Many companies are relatively small and are working under difficult financial circumstances, but their research, which in recent years has become increasingly sophisticated, will change many people’s health and lives. “Research with the support of venture capital is a necessity today to get a broad and vigorous Swedish Life Science industry to compete in the international market with the goal of becoming a world leader.”

Moderator during the day was a financial journalist Lars Frick. The companies that presented themselves were;

Addlife, Bactiguard, Camurus, Dignitana US Inc, Hansa Medical, index Pharma, IRLAB, Karolinska Development, MedCap, Medivir Pharma Moberg, Oasmia Pharmaceutical, Orexo, Redwood Pharma SciBase, and Wnt Reserarch.



(You certainly are still) Welcome to the UK, Stockholm 2017

Yesterday evening I attended for the 3rd year a event that is run by The Swedish Chamber of Commerce in London a event that was called (Are you still) welcome to the UK? of course talking about the Brexit situation.

This started off by The British Ambassador to Sweden David Cairns who said that the UK had a great opportunity to create closer relationships with the rest of the world following the announcement of Brexit plus that he hopes that business will not be affected by this plus the country is very welcoming and gave a “varmt välkommen” to everyone in Swedish.

This was then closely followed on by James Savage, Co-founder of The Local which is a written online newspaper for English written news and he went onto say that Brexit has caused huge issues with the question over immigration, here is Sweden the application for Swedish citizenship tripled after the announcement. He also mentioned the price for difference in applications in different member states will also make it harder for people to stay in the countries they currently reside.



Stefan Backlund a year ago decided to set up a office in London due to this being the number financial place in the world, to set up Trustly that is a fin tech online banking payment solution which they have has a really positive time by now employing 6 people and looking to take another 20/25 people.

Everyone since the announcement seems to have also become experts at trying to make sense of what the future 2 years will look like with the separation from the UK, Garvan Walsh from Brexit Analytics commented that he feels that the UK market is now an emerging market which in one way of another probably is the case.

What I am personally astounded by is that the previous Prime Minister lead us to a referendum and there was no clear plan in place that should the yes we want the UK to leave the European Union there would not be a time as such that everyone is left in the dark or not so, social media today comments on every possible angle of the good, bad plus ugly information that is said.

I think that this has left the brand of the UK in complete confusion on where the question on everyone minds in business, is this a country that we want to do business with or set up a business on the soil of the UK. I also really wonder what people would be talking about had this not actually happened?


Great to showcase Swedish companies in London at BioWednesday

On Wednesday 1st February, One Nucleus had their monthly BioWednesday where for the 2nd year we held the Swedish showcase which was a great success, this was at the lawyers Olswang in the city of London.

There were around 70 delegates who attended the event including the Swedish companies who presented.

Mattias Nystrom, APL

Nima Jokilaakso, Swecare

Anne Dorthe Madsen Brandt, Michael Wamberg and Ulrika Rosdahl, DB Lab

Philip Ridley Smith, Cobra Biologics

Anna Törner, Scandinavian Development Services

Anna Fahlgren, BioReperia

Albin Forslund, Visiba Care

Anders Björlin, Kiwok

Oliver Namin, Min Doktor




It was great to have Swecare part of the delegation as they help their members open doors but are also half supported by the Swedish Government and they arrange many international delegations.

I always love to be in London plus to visit the UK and it never ceases to amaze me the high caliber of knowledge that we have within out sector which I hope will enable patients to be empowered in their daily lives.

New Horizons in Biologics and Bioprocessing

On Thursday 15th December saw the New Horizons in Biologics and Bioprocessing take place at the Waterfront Conference centre in the heart of Stockholm, normally I drive a lot to Stockholm however on this day I took the train and got stuck due to a signal failure so was delayed by 45 minutes, it appears that even the Swedish train system is lacking updating to its rail network.

The event had Johan Rockberg from University of Stockholm, KTH taking about high throughput screening of CHO clones using droplet micro fluidics.

Pall International Sarl also presented their development and application of continuous clarification for CHO cell culture using acoustic technology by Henry Charlton.

I moderated the panel debate with Cobra Biologics, KTH and Pall International Sarl which was great fun and I asked the panelists if they could ask Father Christmas what they would like for work in 2017 what would it be?

The requests were global peace, more money in grants available, a hunger for continuous improvement for life sciences plus also a quicker implementation for technology in clinics and also my request would be that we see some sort of strategy to be put in place so we can at least work together.

Some other thoughts that came out of this debate was that we all agreed that patients need to be more empowered and that we all get the same treatment that’s available and not depending on where we live.

It was great to also listen to Mike Austin from AstraZeneca giving a update on the investment in their production facility in my home town of Söderatlje, they are looking to employ 150 people in the next 2 years. The clinical trials that are currently in phase 3 are going to be made at the Gärtuna site and put into pre filled syringes where they can then ship them off to the clinic so they can get to a patient. There is great is the breadth of disease areas they are now focusing which these are just a few of them respiratory, cardiology oncology and pediatrics.

This was a really interesting conference with technology reaching science fiction.

Scandinavian showcase at BioWednesday in London on 1st February 2017

Swedish delegation for 2016

This year on Wednesday 3rd February we had a Swedish showcase of companies who came as part of a delegation to One Nucleus BioWednesday which was held at the beautiful central London offices of Olswang LLP.

So we are going to the same event in 2017 and very pleased to be having the following companies as part of this Scandinavian delegation to London again on 1st February 2018.

We hope you will be able to attend the event and to see more information about this, here is the link.

Pharma Outsourcing and the published pipeline document for 2016!

On Thursday I presented my thoughts on 2016 in the world of the Life Science Sector at Pharma Outsourcing in Stockholm where there were more than 150 delegates attended. Yes this year has certainly been a political roller coaster but on a whole it seems to have been a good year as everyone in the audience of Pharma Outsourcing in Stockholm thought this.

In this years published “The Swedish Drug Discovery & Development Pipeline 2016” there are 369 projects in the pipeline and 144 of these are in clinical development and Oncology dominating with 60% of the projects being in this disease area, I do question if Sweden has $2.6 billion which it costs on average to get a drug to market plus what will the landscape look like in 10 years if the drug hits the market but unfortunately inevitably only 20% of these will never make it to a patient.

The Pharma Outsourcing presentations were well balanced with virtual companies wanting to find the best resource to help with their development of their projects plus also the outsourcing providers explaining how they can fill that void.

I moderated the panel debate with Pharma Consulting Group, IntervaccLife Science Biznes Consulting, Swecare and myself, it was a great discussion about the question around Standardisation in the way of trying to get people to realise that we need more system thinking when it comes to clinical development.

There was also the big question on where do we want to go in the industry and I really feel that we need some sort of Strategy in place so that we have plan and that would be great to see from the Swedish Government, we have a lot of great work going on but this is not being joined up.

There was also the question around data and the trust that the industry needs from the doctors, I still feel that its quite staggering that are phones know more about us than our doctor and this certainly need to change as the healthcare industry is lacking behind in customer services.

I wonder if this is a issue with time or that they are worried about the future and what this could hold but we as patients are being let down by this plus the promise of personalised medicine which as I see it is just a buzz word at the moment unless you want to pay privately for this service.



Genesis 2016, great to be part of the 16th year and still going strong!

This year was my 3rd year of attending Genesis and its into its 16th year but its always ever evolving, the fringe event was held at Canada House in Trafalgar Square right in the heart of London. The afternoon seminar title was “BioClusters Seminar: Collaboration, Competition and Funding” the visiting delegation were from Montreal, Quebec so it was great to learn about the Life Science companies and innovations that are going on over there.


There was also a panel debate about how to stay competitive being a life science cluster and how do you keep evolving but my conclusion is that with the population size of the UK and health challenges maybe these places will become some sort of community hub?


On Thursday 1st December on a beautiful crisp winter morning in the heart of Westminster, London. Harriet Fear, Chief Executive of One Nucleus opened Genesis and who a real inspiration to me, this year they have won best global membership as well. There were more delegates that have ever that attended, a fully packed schedule for the day with 4 different leadership sessions, workshops and 1-2-1 partnering plus much more.

Mene Pangalos, Executive Vice President to AstraZeneca talked about how AstraZeneca has learned to focus on projects instead of the traditional research strategy they have had and they are seeing results with the amount of papers which have been published and this is being shown in the pipeline with pre clinical projects.


They have a phase 3 molecule being taken forward in DNA damage response that had been shelved but when Pascal joined the board the value was recognised and a collaboration with Moderna, RNA is actually being injected into cells and exciting results are being seen.

They also have a trial currently in animals which is to help regenerate heat failure and there are signs of improvement in cardiac function, this will start being in a clinical trial on the 31st December.

After following AstraZeneca for many years and working with them on their closure sites, I feel its a really exciting time to be a patient as they seem to be certainly open for innovation plus putting their efforts into making a patient better whether that’s with looking at personalised healthcare or the 2 million genome that they have just won the Script Award for.

Mike Ward, Global Director of Content at Scrip did his winners and losers he said that there has been a lag in investment due to political uncertainty in the west but cancer is dominating the market and the company that has had the biggest headache is the Epipen due to the investigation in pricing.

The lunch keynote speaker was Rajesh Agrawal, Deputy Mayor of London for Business and said London really is the best place in the world to do business due to the openness, funding and great talent

I was very proud to be able to chair the workshop “Can Employers Revolutionise Med Tech Financing?” with speakers from Applied Nanodetectors, PWC, APL and Penningtons Manchesphoto-2016-12-01-18-16-26

The short outcome to the debate was that Public Health England should really make the population aware of what the state is of the UK health as 65% of 65 million people being overweight is not the way forward, with 2 million apps available on Apple store there is just to much choice and so much data that doctors are saying that they can not deal with anymore information. Is Investors in People a way forward to get employers to get their workforce having a pride in their well being?